Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020... Nov 23
The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis ... Nov 23
The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
-Advertisements-